IP Library Granted Patent US 7,501,488
Granted Patent B2
US 7,501,488 · App. 10/724,264 · Granted Mar 10, 2009

Proteorhodopsin mutants with improved optical characteristics

Assignee: Genencor International, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,501,488
App. No.
10/724,264
Granted
Mar 10, 2009
Kind
B2
Abstract

The present invention is directed to a proteorhodopsin mutant having improved optical characteristics. One improved optical characteristic is having a lower pH (pK rh ) at which equal concentrations of the acidic and basic spectral form of the proteorhodopsin molecules are present. Another improved optical characteristic is having a smaller difference in maximum absorption wavelength between the basic and the acidic form. The mutant comprises a mutation in a conserved amino acid residue of a proteorhodopsin variant, which causes spectral shifts. A preferred mutation site is a conserved histidine residue at amino acid position 75 of Bac31A8, or position 77 of Hot75m1, or its equivalent position of a proteorhodopsin variant. Another preferred mutation site is a conserved arginine residue at amino acid position 94 of Bac31A8, or position 96 of Hot75m1, or its equivalent position of a proteorhodopsin variant.

Claims (17)

1. A proteorhodopsin mutant having improved optical characteristics, said mutant is a proteorhodopsin variant comprising a mutation in a conserved histidine residue, said proteorhodopsin variant having at least 90% identity with its corresponding naturally occurring proteorhodopsin, said conserved histidine is present at the position equivalent to position 75 of SEQ ID NO: 3 when the proteorhodopsin variant is aligned with SEQ ID NO: 3 for maximum identity, wherein said proteorhodopsin mutant has lower pK rh in comparison with the proteorhodopsin variant.

2. The proteorhodopsin mutant according to claim 1 , wherein said naturally occurring proteorhodopsin comprises SEQ ID NO: 1, 3, 27, 103, 121, 125, 133, 139, 151, or 161.

3. The proteorhodopsin mutant according to claim 2 , wherein said naturally occurring proteorhodopsin comprises SEQ ID NO: 1 or SEQ ID NO: 3.

4. The proteorhodopsin mutant according to claim 1 , wherein said conserved histidine residue is mutated to an amino acid capable of forming a hydrogen bond.

5. The proteorhodopsin mutant according to claim 4 , wherein said amino acid capable of forming a H-bond is asparagine, glutamine, lysine, arginine, tryptophan, serine, threonine, tyrosine, aspartic acid, or glutamic acid.

6. The proteorhodopsin mutant according to claim 5 , wherein said amino acid capable of forming an H-bond is asparagine, glutamine, lysine, tryptophan, aspartic acid, or glutamic acid.

7. The proteorhodopsin mutant according to claim 1 , comprising the amino acid sequence of SEQ ID NO: 165.

8. A method for preparing the proteorhodopsin mutant having improved optical characteristics according to claim 1 , comprising the steps of:

(a) identifying the conserved histidine amino acid residue of the proteorhodopsin variant of claim 1 ,

(b) mutagenizing the conserved histidine amino acid residue, and obtaining proteorhodopsin mutants,

(c) determining the optical characteristics of the proteorhodopsin mutants, and

(d) selecting the proteorhodopsin mutant having improved optical characteristics.

9. The method according to claim 8 , wherein said conserved amino acid residue is mutagenized by site-directed mutagenesis.

10. The proteorhodopsin mutant according to claim 1 , wherein the proteorhodopsin variant has at least 97% identity with the naturally occurring proteorhodopsin.

11. A proteorhodopsin mutant having improved optical characteristics, said mutant is a proteorhodopsin variant comprising a mutation in a conserved histidine residue, said proteorhodopsin variant is selected from the group consisting of SEQ ID NO: 1, 3, 27, 103, 121, 125, 133, 139, 151, and 161, or having at least 90% identity with the naturally occurring proteorhodopsin, said conserved histidine is present at the position equivalent to position 75 of SEQ ID NO: 3 when the proteorhodopsin variant is aligned with SEQ ID NO: 3 for maximum identity, wherein said proteorhodopsin mutant has lower pK rh in comparison with the proteorhodopsin variant.

12. The proteorhodopsin mutant according to claim 11 , wherein the proteorhodopsin variant has at least 97% identity with the naturally occurring proteorhodopsin.

13. The proteorhodopsin mutant according to claim 11 , wherein the naturally occurring proteorhodopsin comprises the amino acid sequence of SEQ ID NO: 3.

Assignments (2)
CHANGE OF NAME Recorded Mar 1, 2010
From: GENENCOR INTERNATIONAL, INC.
To: DANISCO US INC.
Reel/Frame 024006/0253 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2004
From: JENSEN, RASMUS B.; KELEMEN, BRADLEY ROGER
To: GENENCOR INTERNATIONAL, INC.
Reel/Frame 015335/0677 →
Continuity (2)
Provisional Application 6042951800 · Nov 26, 2002
Related Publication 20050095605A1 · May 5, 2005